Brookline Raises CRISPR EPS Forecast

Summary

Brookline Capital Management has increased its Q3 2025 earnings estimates for CRISPR Therapeutics (NASDAQ:CRSP) from ($1.25) to ($1.23) per share. The firm also estimated future earnings of ($5.34) EPS for FY2025 and $44.54 EPS for FY2029. Analysts have mixed ratings on the stock with a consensus target price of $71.60. The company’s recent earnings report showed a loss of ($1.29) EPS, beating estimates, but revenue underperformed at $0.89 million. Institutional investors hold 69.20% of the stock, indicating strong interest. Market Beat

Impact Analysis

1. Business Overview Analysis

• CRISPR Therapeutics operates primarily in the biotechnology industry, focusing on gene-editing technologies. Its core business model revolves around developing CRISPR/Cas9 technology for therapeutic applications, which represents a significant and innovative revenue stream in the biotech field.
• The company holds a strong market position due to its pioneering role in gene-editing technologies. However, it faces competitive pressures from other biotech firms developing similar therapies, including those employing alternative gene-editing technologies.
• Recent events impacting the business include positive earnings compared to expectations, despite revenue shortfalls, and strong institutional investor interest with a 69.20% holding. Additionally, significant insider trading activity indicates confidence in the company’s potential. Market Beat+ 2

2. Financial Statement Analysis

• Income Statement: The company showed a loss of ($1.29) EPS in its recent earnings report, exceeding expectations but still indicating a lack of profitability. Revenue was notably low at $0.89 million, suggesting challenges in monetizing its technology despite beating EPS estimates. Market Beat
• Balance Sheet: The analysis does not provide specific balance sheet details, but institutional investor interest may imply perceived quality in assets or future potential.
• Cash Flow: Lacking explicit details, an assessment of cash flow generation, investment requirements, and financing activities cannot be made from the provided data.
• Financial Ratios: Without detailed financial statements, calculating specific ratios such as ROE, ROA, or margin trends is not feasible.

3. Valuation Assessment (Optional)

• The consensus target price for CRISPR Therapeutics is $71.60, which can be compared to the latest trading price to assess potential undervaluation or overvaluation. Market Beat

4. Opportunity Analysis (Optional)

• The company may explore market expansion opportunities in gene editing applications and related biotechnology fields.